HPV58 E6 Specific Neutra™ Antibody Products

Are prolonged therapeutic development cycles or insufficient targeting of HPV58 E6 oncoprotein compromising your research? Creative Biolabs' HPV58 E6 specific Neutra™ antibodies leverage high-affinity monoclonal engineering and advanced epitope mapping to deliver unparalleled specificity, enabling precise neutralization of E6-driven oncogenic activity and accelerating therapeutic discovery against HPV-associated malignancies.

Introduction to HPV58 E6

Human papillomavirus 58 protein E6 (HPV58 E6) is a critical oncoprotein encoded by high-risk HPV type 58, directly implicated in viral persistence and malignant transformation. As a key driver of carcinogenesis, HPV58 E6 disrupts host tumor suppressor pathways, enabling unchecked cellular proliferation and genomic instability.

• Basic Information

HPV58 E6 is a 150-amino-acid oncoprotein expressed during the early stages of HPV infection. It is highly conserved among high-risk HPV strains, sharing structural and functional homology with E6 proteins from HPV16 and HPV18. Its primary role involves hijacking host ubiquitin-proteasome systems to degrade tumor suppressors, facilitating viral replication and carcinogenesis.

• Structure

HPV58 E6 comprises two zinc-binding domains (Zn1 and Zn2) connected by a flexible linker. The Zn1 domain mediates interactions with cellular partners such as E6-associated protein (E6AP), while the Zn2 domain binds p53 and other tumor suppressors. Structural studies reveal that conformational flexibility in the linker region enables E6 to engage diverse host targets, a feature critical for its oncogenicity.

Fig.1 E6/E6* transcription patterns of HPV58.¹

• Related Signaling Pathways

HPV58 E6 orchestrates carcinogenesis through dual mechanisms:

- p53 Degradation: By forming an E6-E6AP-p53 ternary complex, E6 facilitates ubiquitination and proteasomal degradation of p53, abolishing apoptosis and DNA repair.

- Telomerase Activation: E6 upregulates telomerase reverse transcriptase (TERT), immortalizing infected cells.

- Immune Evasion: E6 suppresses interferon signaling and antigen presentation, enabling immune escape.

• Related Diseases

HPV58 is a high-risk genotype predominantly linked to cervical cancer, accounting for 4-7% of cases globally, with higher prevalence in Asia. Persistent HPV58 E6 expression drives cervical intraepithelial neoplasia (CIN) progression, vulvar squamous cell carcinoma, and anal cancers. Its oncogenic potency underscores the urgency of targeting E6 for therapeutic intervention.

Applications of HPV58 E6 Neutralizing Antibodies

• Diagnostic Development

HPV58 E6 antibodies enable highly sensitive detection of E6 in clinical samples, distinguishing active infections from latent HPV. They are critical for developing HPV genotyping assays and monitoring treatment responses in precancerous lesions.

• Therapeutic Intervention

Neutralizing antibodies block E6-E6AP-p53 interactions, reinstating tumor suppressor activity and triggering apoptosis in malignant cells. Preclinical studies demonstrate their efficacy in reducing cervical tumor growth and sensitizing cells to chemotherapy.

• Vaccine Design

E6-specific antibodies inform the development of prophylactic and therapeutic vaccines by identifying immunodominant epitopes. These antibodies serve as benchmarks for evaluating vaccine-induced neutralizing responses in clinical trials.

• Research Toolkits

Used in immunohistochemistry and flow cytometry, these antibodies study E6 expression dynamics during infection and carcinogenesis. They are indispensable for studying E6's role in immune evasion and genome instability.

Our Anti-HPV58 E6 Antibodies

Creative Biolabs' HPV58 E6 specific antibodies are engineered to block E6-host protein interactions with exceptional precision.

- Epitope Specificity: Antibodies target the Zn1 domain and E6AP-binding interface, preventing E6-mediated p53 degradation.

- Functional Validation: Validated in ELISA, immunoprecipitation, and neutralization assays, these antibodies inhibit E6 oncogenic activity in vitro and in vivo.

- Therapeutic Potential: By restoring p53 function, they induce apoptosis in HPV58-positive cancer cells, offering a pathway-specific therapeutic strategy.

Creative Biolabs offers HPV58 E6 specific Neutra™ antibodies, which are considered the gold standard for precision oncology research and therapeutic development. Engineered for unmatched affinity and specificity, they empower breakthroughs in HPV-associated disease management.

Contact our scientific team today to explore custom solutions for your HPV58 E6 research or therapeutic project.

REFERENCE

1. Olmedo-Nieva, Leslie, et al. "The role of E6 spliced isoforms (E6*) in human papillomavirus-induced carcinogenesis." Viruses 10.1 (2018): 45. Distributed under Open Access license CC BY 4.0. The image was modified by extracting and using only part of the original image. https://doi.org/10.3390/v10010045